Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can targeted radiation outperform surgery for a tough throat cancer?

NCT ID NCT07781098

Disease control Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial investigates whether intensity-modulated radiotherapy (IMRT) can improve local control in patients with early-stage glottic (voice box) cancer that is poorly differentiated—a type that tends to recur more often after surgery. Adults with T1-T2N0M0 glottic squamous cell carcinoma, who have either had surgery or will receive radiation as their primary treatment, will undergo IMRT targeting the larynx and nearby lymph nodes. The study aims to see if this approach reduces the chance of cancer returning in the same area over three years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intensity-modulated radiotherapy (IMRT)
What this could lead to
If successful, this could establish radiotherapy as a better first-line option than surgery for poorly differentiated early-stage glottic cancer, potentially improving local control and survival.
What could go wrong
This is a small, single-arm phase II trial, so results may not be definitive. Radiotherapy carries risks like throat irritation, swallowing difficulties, and potential damage to nearby tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 38 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years, any gender 2. Histologically proven glottic squamous cell carcinoma 3. T1 T2N0M0 glottic laryngeal carcinoma with poor differentiation (moderate poor differentiation counted as poor differentiation) 4. Subjects undergoing curative intent surgery must be enrolled 4 8 weeks after operation. 5. No prior chemoradiotherapy or antineoplastic therapy 6. ECOG PS 0 1 7. Written informed consent provided Exclusion Criteria: 1. Moderately or well differentiated tumours 2. Prior chemotherapy or other antineoplastic agents 3. Prior head and neck irradiation 4. Previous participation in another clinical trial 5. Severe allergic history including contrast media allergy 6. Pregnancy or lactation 7. Uncontrolled acute infection 8. Drug/substance abuse, chronic heavy drinking, HIV infection 9. Uncontrolled concomitant malignant disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early stage glottic squamous cell carcinoma with poor differentiation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glottis squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early stage glottic squamous cell carcinoma with poor differentiation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Second Affiliated Hospital Of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China